VictoryShares International High Div Volatility Wtd ETF CID 深 滬
等待開盤 08-23 09:30:00 美东时间
33.015
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 33.015
- 總市值 1980.90万
- 52周最高 34.2569
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 27.0851
- 委 比 0.00%
- 總股本 60.00万
- 歷史最高 34.2569
- 量 比 0
- 振 幅 0.00%
- 歷史最低 12.3603
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Shares of Dayforce Inc (NYSE:DAY) rose sharply in pre-market trading. Bloomberg...
08-18 18:51
鼎优乐短期仍存短缺问题 再鼎医药预计旗下PARP抑制剂一线份额将扩大|直击业绩会
①今日举行的业绩会中，再鼎医药管理层对部分主要产品销售情况以及下半年业绩展望做出了介绍； ②再鼎医药还就鼎优乐药物短缺问题，以及肿瘤类、精神类药物管线进展和商业化布局等问题做出了回应。
08-08 16:02
CASI Pharmaceuticals shares are trading higher after the company announced FDA clearance for CID-103.
CASI Pharmaceuticals shares are trading higher after the company announced FDA ...
08-04 23:39
CINNO Research：1H’25中国乘用车中控CID搭载量同比增长12%
根据CINNO Research数据显示，1H’25中国乘用车中控CID搭载量为1,284万，同比增长12%，搭载率高达98%；其中，新能源乘用车和燃油乘用车的CID平圴尺寸分别为14.1”和11.0”，同比分别增加0.4”和0.5”。
07-30 16:13
CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program
CASI Pharmaceuticals ( ($CASI) ) has issued an announcement. On July 21, 2025, ...
07-22 18:28
LUCID CAPITAL MARKETS Reiterates Buy on BioXcel Therapeutics, Maintains $66 Price Target
LUCID CAPITAL MARKETS analyst Elemer Piros reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $66 price target.
07-15 21:54
每年资金缺口达4200亿美元！为什么金融议题必须包括性别视角？
登录新浪财经APP 搜索【信披】查看更多考评等级 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市...
07-03 17:54
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.
07-02 17:55
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.
07-01 01:13
Jaguar Health Pursues EU Approval For Canalevia To Treat General Dog Diarrhea
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possibility of
06-25 21:03
